388 related articles for article (PubMed ID: 25656368)
1. Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow.
Jensen EP; Poulsen SS; Kissow H; Holstein-Rathlou NH; Deacon CF; Jensen BL; Holst JJ; Sorensen CM
Am J Physiol Renal Physiol; 2015 Apr; 308(8):F867-77. PubMed ID: 25656368
[TBL] [Abstract][Full Text] [Related]
2. GLP-1-induced renal vasodilation in rodents depends exclusively on the known GLP-1 receptor and is lost in prehypertensive rats.
Jensen EP; Møller S; Hviid AV; Veedfald S; Holst JJ; Pedersen J; Ørskov C; Sorensen CM
Am J Physiol Renal Physiol; 2020 Jun; 318(6):F1409-F1417. PubMed ID: 32390511
[TBL] [Abstract][Full Text] [Related]
3. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury.
Hirata Y; Kurobe H; Nishio C; Tanaka K; Fukuda D; Uematsu E; Nishimoto S; Soeki T; Harada N; Sakaue H; Kitagawa T; Shimabukuro M; Nakaya Y; Sata M
Eur J Pharmacol; 2013 Jan; 699(1-3):106-11. PubMed ID: 23220706
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors.
Ronn J; Jensen EP; Wewer Albrechtsen NJ; Holst JJ; Sorensen CM
Physiol Rep; 2017 Dec; 5(23):. PubMed ID: 29233907
[TBL] [Abstract][Full Text] [Related]
5. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury.
Goto H; Nomiyama T; Mita T; Yasunari E; Azuma K; Komiya K; Arakawa M; Jin WL; Kanazawa A; Kawamori R; Fujitani Y; Hirose T; Watada H
Biochem Biophys Res Commun; 2011 Feb; 405(1):79-84. PubMed ID: 21215253
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.
Schlatter P; Beglinger C; Drewe J; Gutmann H
Regul Pept; 2007 Jun; 141(1-3):120-8. PubMed ID: 17276524
[TBL] [Abstract][Full Text] [Related]
7. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men.
Asmar A; Simonsen L; Asmar M; Madsbad S; Holst JJ; Frandsen E; Moro C; Jonassen T; Bülow J
Am J Physiol Endocrinol Metab; 2015 Apr; 308(8):E641-9. PubMed ID: 25670826
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis.
Marzioni M; Alpini G; Saccomanno S; Candelaresi C; Venter J; Rychlicki C; Fava G; Francis H; Trozzi L; Glaser S; Benedetti A
Gastroenterology; 2007 Jul; 133(1):244-55. PubMed ID: 17631146
[TBL] [Abstract][Full Text] [Related]
9. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
[TBL] [Abstract][Full Text] [Related]
11. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-Like Peptide-1 Receptor Activation Does not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury.
Eriksson L; Saxelin R; Röhl S; Roy J; Caidahl K; Nyström T; Hedin U; Razuvaev A
J Vasc Res; 2015; 52(1):41-52. PubMed ID: 25966620
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Ban K; Kim KH; Cho CK; Sauvé M; Diamandis EP; Backx PH; Drucker DJ; Husain M
Endocrinology; 2010 Apr; 151(4):1520-31. PubMed ID: 20172966
[TBL] [Abstract][Full Text] [Related]
14. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat.
Bucinskaite V; Tolessa T; Pedersen J; Rydqvist B; Zerihun L; Holst JJ; Hellström PM
Neurogastroenterol Motil; 2009 Sep; 21(9):978-e78. PubMed ID: 19453518
[TBL] [Abstract][Full Text] [Related]
15. Autoregulation of renal blood flow (RBF) with and without participation of afferent arterioles.
Ofstad J; Iversen BM; Mørkrid L; Sekse I
Acta Physiol Scand; 1987 May; 130(1):25-32. PubMed ID: 3591388
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.
Crajoinas RO; Oricchio FT; Pessoa TD; Pacheco BP; Lessa LM; Malnic G; Girardi AC
Am J Physiol Renal Physiol; 2011 Aug; 301(2):F355-63. PubMed ID: 21593184
[TBL] [Abstract][Full Text] [Related]
17. Role of connexin40 in the autoregulatory response of the afferent arteriole.
Sorensen CM; Giese I; Braunstein TH; Brasen JC; Salomonsson M; Holstein-Rathlou NH
Am J Physiol Renal Physiol; 2012 Sep; 303(6):F855-63. PubMed ID: 22811484
[TBL] [Abstract][Full Text] [Related]
18. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
19. Does glucagon-like peptide-1 induce diuresis and natriuresis by modulating afferent renal nerve activity?
Katsurada K; Nandi SS; Sharma NM; Zheng H; Liu X; Patel KP
Am J Physiol Renal Physiol; 2019 Oct; 317(4):F1010-F1021. PubMed ID: 31390233
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
Ojima A; Ishibashi Y; Matsui T; Maeda S; Nishino Y; Takeuchi M; Fukami K; Yamagishi S
Am J Pathol; 2013 Jan; 182(1):132-41. PubMed ID: 23159951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
